Tag
Many people with hidradenitis suppurativa (HS) aren’t getting treatments that reach beyond the skin. A GHLF survey of 462 people reporting HS symptoms, presented at ACR Convergence 2026, found that people taking DMARDs reported fewer painful HS symptoms — and that people without a rheumatic condition, such as rheumatoid arthritis or lupus, were often left out of these treatment options.
Fewer than 1 in 3 people with myositis are very satisfied with their treatment. A new GHLF survey, presented at ACR Convergence 2026, shows what patients most want from care: moving more easily, having more energy, and staying independent.
Monoclonal antibodies can sound intimidating, but the idea behind them is simple: they're designed to work like your body's own natural defenses. Learn how these "-mab" medications work, how they're given, and what questions to ask your care team.
Vaccines and monoclonal antibodies both help protect against disease — but they work in different ways. Learn how each one supports your immune system, and why having more than one tool can matter, especially for people who don't respond well to vaccines alone.
By 
By 
